News Releases

Date	Title and Summary	View
Dec 20, 2021	FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
Dec 17, 2021	Johnson & Johnson to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Dec 15, 2021	Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
Dec 11, 2021	Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
Dec 11, 2021	New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
Dec 10, 2021	Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Dec 10, 2021	Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® ▼ (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy
Dec 09, 2021	World Health Organization Strategic Advisory Group of Experts (SAGE) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster
Dec 09, 2021	Johnson & Johnson Appoints Senior Leaders to Executive Committee
Dec 05, 2021	Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses